The groundbreaking method may prove useful in treating myriad malignancies, inflammatory diseases and rare genetic disorders.
Lipid nanoparticles (LNP) were used to deliver modified messenger RNA to treat inflammatory bowel diseases and other diseases.
Prof. Dan Peer, Molecular Cell Biology at TAU's Faculty of Life Sciences, led the research for the new study.
Over the past few years, lipid carriers encapsulating messenger RNAs (mRNAs) have been shown to be extremely useful in altering the protein expressions for a host of diseases. But directing this information to specific cells has remained a major challenge.
"In our new research, we utilized mRNA-loaded carriers — nanovehicles carrying a set of genetic instructions via a biological platform called ASSET — to target the genetic instructions of an anti-inflammatory protein in immune cells," says Prof. Peer.